Quality
Return on invested capital, after tax
1.8% Computed
From the FY2025 filing
ValueScreener company report
Takeda Pharmaceutical Company Limited (TAK)
NYSE / Healthcare / Drug Manufacturers - Specialty & Generic
Share price
19.45 USD Market dataClose of Oct 15, 2026Market capitalisation
61.73B USD Market dataClose of Oct 15, 2026- Market data
- Oct 15, 2026
- Filed accounts
- FY2025, filed Jun 25, 2025
- Ratios computed
- Oct 14, 2026
- Filed years
- 9, FY2017 to FY2025
Four kinds of sourceSEC filingCompany statementMarket dataComputedWhat each means
- SEC filingFiled with the SEC
- Read from a statement the company filed with the SEC, with the form, fiscal year, filing date and accession beside it.
- Company statementCompany statement
- What the company says about itself in a filing: an 8-K item, the auditor, its own segment names.
- Market dataMarket data
- Prices, market value and what analysts publish, with the date they are as of.
- ComputedComputed by ValueScreener
- Worked out by us from the other three, with the inputs and the formula one press away. A score is a research output, not a rating or a recommendation.
Reading
1 of 10
Overview
What the business is, what it costs, and how it reads on four questions.
Market dataSEC filingComputed
Four questions, at a glance
Financial strength
Debt to equity
0.73 Computed
From the FY2025 filing
Valuation
Price to earnings
88.60x Computed
FY2025 accounts, priced at the latest close
Cash generation
Free cash flow yield
9.0% Computed
FY2025 accounts, priced at the latest close
Revenue and net income, by fiscal year
- Named tests met
- 1 of 30 Which tests
The business, and the score behind its five axes
The reading, in brief
- Is it cheap
Price to earnings is 88.60x at the close of 2026-10-15 on FY2025 figures; the lines are 15.00x (Graham's defensive ceiling) and, by market convention, 10.00x, 25.00x and 40.00x, and this sits above the highest.
Today, against the Healthcare sector (222 companies), 88.60x sits at the 90th percentile; the middle half of that group runs from 13.32x to 42.36x.
- Is it good
Return on invested capital was 1.8% in FY2025, in the band labelled "Likely below the cost of capital" (below 8.0%), on lines anchored on Damodaran's cost-of-capital data, suggesting returns below the usual cost of the capital employed.
Today, against the Healthcare sector (192 companies), 1.8% sits at the 43rd percentile; the middle half of that group runs from -20.2% to 14.2%.
- Is it safe
Interest coverage was 1.63x in FY2025, in the band labelled "Speculative grade" (1.50x to 3.00x), on lines anchored on Damodaran's interest-coverage table.
- Year by year against peers
- Whether Takeda Pharmaceutical Company Limited's return on equity stayed above the median of the Drug Manufacturers - Specialty & Generic industry, year by year. (FY2019 to FY2025, 7 fiscal years of Takeda Pharmaceutical Company Limited with a comparable figure)
- The direction
- Which way Takeda Pharmaceutical Company Limited's gross margin has moved, and how steadily. (FY2016 to FY2025, 10 filed years of Takeda Pharmaceutical Company Limited)
- What could explain it
- What in Takeda Pharmaceutical Company Limited's filed statements could explain the movements. (6 readings drawn from the statement lines Takeda Pharmaceutical Company Limited filed)
- What to check next
- What to check next on Takeda Pharmaceutical Company Limited, and where in its filings. (5 questions for Takeda Pharmaceutical Company Limited)
- In one paragraph
- One paragraph on Takeda Pharmaceutical Company Limited's returns, cash, balance sheet and price. (15 of sixteen figures read for Takeda Pharmaceutical Company Limited)
These are TAK’s filed figures. The research desk says what they mean, against peers and its own years, with what to check next.
Research TAKPart of Serious. New accounts start with 30 days of Professional, free, no card.
2 of 10
What changed
The newest filing, what it moved, and when the next one is due.
SEC filingCompany statement
The newest accounts on file are the FY2025 annual report: 20-F, filed Jun 25, 2025, accession 0001395064-25-000095.
3 of 10
Quality
The returns the business earns on its capital, and the margins behind them.
SEC filingComputed
| Figure | Value, source and document |
|---|---|
| Return on invested capital, after tax | 1.8% ComputedFY2025 20-F, filed Jun 25, 2025, 0001395064-25-000095 |
| Return on equity | 1.6% ComputedFY2025 20-F, filed Jun 25, 2025, 0001395064-25-000095 |
| Return on capital employed, pre-tax | 2.9% ComputedFY2025 20-F, filed Jun 25, 2025, 0001395064-25-000095 |
| Return on assets | 0.8% ComputedFY2025 20-F, filed Jun 25, 2025, 0001395064-25-000095 |
| Gross margin | 65.5% ComputedFY2025 20-F, filed Jun 25, 2025, 0001395064-25-000095 |
| Operating margin | 7.5% ComputedFY2025 20-F, filed Jun 25, 2025, 0001395064-25-000095 |
| Net margin | 2.4% ComputedFY2025 20-F, filed Jun 25, 2025, 0001395064-25-000095 |
TAK 2.4%
-24.6%28.2%
4 of 10
Financial strength
What it owes against what it owns, and whether it can meet what falls due.
SEC filingComputedCompany statement
| Figure | Value, source and document |
|---|---|
| Debt to equity | 0.73 ComputedFY2025 20-F, filed Jun 25, 2025, 0001395064-25-000095 |
| Current ratio | 1.01 ComputedFY2025 20-F, filed Jun 25, 2025, 0001395064-25-000095 |
| Quick ratio | 0.52 ComputedFY2025 20-F, filed Jun 25, 2025, 0001395064-25-000095 |
| Interest coverage | 1.63x ComputedFY2025 20-F, filed Jun 25, 2025, 0001395064-25-000095 |
| Altman Z-score | 1.30 ComputedClose of Oct 15, 2026 · FY2025 20-F, filed Jun 25, 2025, 0001395064-25-000095 |
| Net debt | 4.70T ComputedFY2025 20-F, filed Jun 25, 2025, 0001395064-25-000095 |
The balance sheet, line by line
Financial health
What Takeda Pharmaceutical Company Limited owned and owed at the end of fiscal 2025, from the balance sheet it filed (20-F, filed Jun 25, 2025, 0001395064-25-000095).
| Total assets | 14.25T FiledFY2025 20-F, filed Jun 25, 2025 |
|---|---|
| Total liabilities | 7.31T FiledFY2025 20-F, filed Jun 25, 2025 |
| Shareholders' equity | 6.94T FiledFY2025 20-F, filed Jun 25, 2025 |
| Cash | 385.11B FiledFY2025 20-F, filed Jun 25, 2025 |
| Total debt | 5.09T FiledFY2025 20-F, filed Jun 25, 2025 |
| Net debt | 4.70T |
| Current ratio | 1.01 |
| Debt to equity | 0.73 |
Read from the filed balance sheet for each year, with the income statement of the same year supplying operating profit where a ratio needs it. Nothing here is a view on whether this company is sound.
5 of 10
Valuation context
What the market charges for it, against its own record and companies like it.
Market dataSEC filingComputed
| Figure | Value, source and document |
|---|---|
| Price to earnings | 88.60x ComputedClose of Oct 15, 2026 · FY2025 20-F, filed Jun 25, 2025, 0001395064-25-000095 |
P/E on trailing twelve monthsWhy n/aA trailing figure needs 4 filed quarters with the dates they were filed on, and we hold 0 for this company. Nothing is drawn rather than a line built from fewer. | n/a ComputedClose of Oct 15, 2026 · Trailing four quarters, each as known on the day; the quarterly filings are listed under Filings |
| Price to book | 1.38x ComputedClose of Oct 15, 2026 · FY2025 20-F, filed Jun 25, 2025, 0001395064-25-000095 |
| Price to sales | 2.09x ComputedClose of Oct 15, 2026 · FY2025 20-F, filed Jun 25, 2025, 0001395064-25-000095 |
| Enterprise value to EBIT | 41.64x ComputedClose of Oct 15, 2026 · FY2025 20-F, filed Jun 25, 2025, 0001395064-25-000095 |
| Enterprise value to EBITDA | 12.92x ComputedClose of Oct 15, 2026 · FY2025 20-F, filed Jun 25, 2025, 0001395064-25-000095 |
Price to earnings over growthWhy n/aWe do not hold this figure for this company, so there is nothing to show. | n/a ComputedClose of Oct 15, 2026 · FY2025 20-F, filed Jun 25, 2025, 0001395064-25-000095 |
Diluted earnings per shareWhy n/aThe FY2025 filing carries no diluted earnings per share we could read. | n/a FiledFY2025 20-F, filed Jun 25, 2025, 0001395064-25-000095 |
Graham numberWhy n/aWe do not hold this figure for this company, so there is nothing to show. | n/a ComputedFY2025 20-F, filed Jun 25, 2025, 0001395064-25-000095 |
We publish no fair value or price target of our own. Value TAK on your own assumptions in the DCF workbench, starting from the filed figures.
Its own record, and companies like it
Valuation
What the market charges for Takeda Pharmaceutical Company Limited today, and the multiples it has carried. No value of ours: the figures are the filings’ and the market’s.
| Share price | 19.45 USD |
|---|---|
| Market capitalisation | 61.73B USD |
| Enterprise value to EBITDA | 12.92x |
| Graham number | n/a |
| Diluted earnings per share, FY2016 | n/a |
Price to earnings on trailing twelve months: A trailing figure needs 4 filed quarters with the dates they were filed on, and we hold 0 for this company. Nothing is drawn rather than a line built from fewer.
Companies like Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Limited (TEVA)Market cap 47.91B USD
- Haleon plc (HLN)Market cap 43.71B USD
- Viatris Inc. (VTRS)Market cap 20.93B USD
- Elanco Animal Health Incorporated (ELAN)Market cap 11.76B USD
- Zoetis Inc. (ZTS)Market cap 32.41B USD
Same industry (Drug Manufacturers - Specialty & Generic) and size band (Large, 10B to 200B), nearest in market value, net margin and current ratio. Each of those counts equally, by how many of the companies considered sit between the two on it. Closest first: the order is likeness and nothing else.
6 of 10
Cash generation
Whether profit arrives as cash, and what is paid back to shareholders.
SEC filingComputed
| Figure | Value, source and document |
|---|---|
| Free cash flow yield | 9.0% ComputedClose of Oct 15, 2026 · FY2025 20-F, filed Jun 25, 2025, 0001395064-25-000095 |
| Free cash flow | 856.39B JPY ComputedFY2025 20-F, filed Jun 25, 2025, 0001395064-25-000095 |
| Free cash flow margin | 18.7% ComputedFY2025 20-F, filed Jun 25, 2025, 0001395064-25-000095 |
Dividend yieldWhy n/aThe newest cash flow statement on file ended more than fifteen months ago, so it says nothing about today's yield. | n/a ComputedClose of Oct 15, 2026 · FY2025 20-F, filed Jun 25, 2025, 0001395064-25-000095 |
| Payout ratio | 280.3% ComputedFY2025 20-F, filed Jun 25, 2025, 0001395064-25-000095 |
7 of 10
Filings
Every figure, the year it is for and the document it was read from.
SEC filingMarket data
The filed figures
Computed from the accounts this company filed with the SEC and, in a ratio with a price in it, the last close, dated on this page. Every filed figure below carries the fiscal year and the filing date its accounts were read from, and every blank carries the reason it is blank. Nothing here is a view on this company.
| Figure | Value | Year | As of |
|---|---|---|---|
| 88.60x | FY2025 | Oct 15, 2026 | |
FormulaShare price / earnings per share. Where the filing states no earnings per share this listing can be priced on, which is every 20-F and 40-F filer because theirs is stated per ordinary share, it is market capitalisation / net income: the same multiple, undiluted. As ofThe close on Oct 15, 2026, over the filed figures of FY2025: a price is in this figure, and it moved after the filing. Form20-FFiledJun 25, 2025PeriodFY2025Accession0001395064-25-000095What we read from itIncome statementFY2025Open on SEC.gov, accession 0001395064-25-000095, leaves this page and opens in a new tab | |||
| 1.38x | FY2025 | Oct 15, 2026 | |
FormulaMarket capitalisation / shareholders equity As ofThe close on Oct 15, 2026, over the filed figures of FY2025: a price is in this figure, and it moved after the filing. Form20-FFiledJun 25, 2025PeriodFY2025Accession0001395064-25-000095What we read from itBalance sheetFY2025Open on SEC.gov, accession 0001395064-25-000095, leaves this page and opens in a new tab | |||
| 41.64x | FY2025 | Oct 15, 2026 | |
Formula(Market capitalisation + total debt - cash) / operating income, or over the filing's own EBIT (income before tax + interest expense) where the filer tags no operating line, as Johnson & Johnson does not in any of its ten filed years. As ofThe close on Oct 15, 2026, over the filed figures of FY2025: a price is in this figure, and it moved after the filing. Form20-FFiledJun 25, 2025PeriodFY2025Accession0001395064-25-000095What we read from itIncome statementFY2025Open on SEC.gov, accession 0001395064-25-000095, leaves this page and opens in a new tabForm20-FFiledJun 25, 2025PeriodFY2025Accession0001395064-25-000095What we read from itBalance sheetFY2025Open on SEC.gov, accession 0001395064-25-000095, leaves this page and opens in a new tab | |||
| 9.0% | FY2025 | Oct 15, 2026 | |
FormulaFree cash flow per share / share price x 100 As ofThe close on Oct 15, 2026, over the filed figures of FY2025: a price is in this figure, and it moved after the filing. Form20-FFiledJun 25, 2025PeriodFY2025Accession0001395064-25-000095What we read from itCash flow statementFY2025Open on SEC.gov, accession 0001395064-25-000095, leaves this page and opens in a new tab | |||
| 1.8% | FY2025 | Jun 25, 2025 | |
FormulaVendor trailing-twelve-month return on invested capital where one is published, which uses after-tax operating profit over total assets less current liabilities. Otherwise our own recompute: NOPAT / (shareholders equity + total debt - cash) x 100, where NOPAT is the filed operating profit after tax, or the filing's own EBIT after tax where the filer tags no operating line. As ofThe filing date of the statements below, for FY2025. Form20-FFiledJun 25, 2025PeriodFY2025Accession0001395064-25-000095What we read from itIncome statementFY2025Open on SEC.gov, accession 0001395064-25-000095, leaves this page and opens in a new tabForm20-FFiledJun 25, 2025PeriodFY2025Accession0001395064-25-000095What we read from itBalance sheetFY2025Open on SEC.gov, accession 0001395064-25-000095, leaves this page and opens in a new tab | |||
| n/a | FY2025 | Oct 15, 2026 | |
| n/a The newest cash flow statement on file ended more than fifteen months ago, so it says nothing about today's yield. | |||
FormulaCommon dividends paid in the latest filed year / market capitalisation x 100. n/a where the filing cannot support it: a special or first-year payment, a total that mixes preferred dividends, or a cash-flow statement over 15 months old. As ofThe close on Oct 15, 2026, over the filed figures of FY2025: a price is in this figure, and it moved after the filing. Form20-FFiledJun 25, 2025PeriodFY2025Accession0001395064-25-000095What we read from itCash flow statementFY2025Open on SEC.gov, accession 0001395064-25-000095, leaves this page and opens in a new tab | |||
| 0.73 | FY2025 | Jun 25, 2025 | |
FormulaTotal debt / shareholders equity As ofThe filing date of the statements below, for FY2025. Form20-FFiledJun 25, 2025PeriodFY2025Accession0001395064-25-000095What we read from itBalance sheetFY2025Open on SEC.gov, accession 0001395064-25-000095, leaves this page and opens in a new tab | |||
| 1.01 | FY2025 | Jun 25, 2025 | |
FormulaCurrent assets / current liabilities As ofThe filing date of the statements below, for FY2025. Form20-FFiledJun 25, 2025PeriodFY2025Accession0001395064-25-000095What we read from itBalance sheetFY2025Open on SEC.gov, accession 0001395064-25-000095, leaves this page and opens in a new tab | |||
| 2.09x | FY2025 | Oct 15, 2026 | |
FormulaMarket capitalisation / revenue As ofThe close on Oct 15, 2026, over the filed figures of FY2025: a price is in this figure, and it moved after the filing. Form20-FFiledJun 25, 2025PeriodFY2025Accession0001395064-25-000095What we read from itIncome statementFY2025Open on SEC.gov, accession 0001395064-25-000095, leaves this page and opens in a new tab | |||
| n/a | FY2025 | Oct 15, 2026 | |
| n/a The filed income statement reports no earnings per share. | |||
FormulaPrice to earnings / the annual earnings growth rate, in percentage points As ofThe close on Oct 15, 2026, over the filed figures of FY2025: a price is in this figure, and it moved after the filing. Form20-FFiledJun 25, 2025PeriodFY2025Accession0001395064-25-000095What we read from itIncome statementFY2025Open on SEC.gov, accession 0001395064-25-000095, leaves this page and opens in a new tab | |||
| 1.30 | FY2025 | Oct 15, 2026 | |
Formula1.2 x working capital/assets + 1.4 x retained earnings/assets + 3.3 x EBIT/assets + 0.6 x market value of equity/total liabilities + 1.0 x revenue/assets As ofThe close on Oct 15, 2026, over the filed figures of FY2025: a price is in this figure, and it moved after the filing. Form20-FFiledJun 25, 2025PeriodFY2025Accession0001395064-25-000095What we read from itIncome statementFY2025Open on SEC.gov, accession 0001395064-25-000095, leaves this page and opens in a new tabForm20-FFiledJun 25, 2025PeriodFY2025Accession0001395064-25-000095What we read from itBalance sheetFY2025Open on SEC.gov, accession 0001395064-25-000095, leaves this page and opens in a new tab | |||
| -2.73 | FY2025 | Jun 25, 2025 | |
FormulaAn eight-variable index of year-on-year changes in receivables, gross margin, asset quality, revenue, depreciation, overheads, leverage and accruals As ofThe filing date of the statements below, for FY2025. Form20-FFiledJun 25, 2025PeriodFY2025Accession0001395064-25-000095What we read from itIncome statementFY2025Open on SEC.gov, accession 0001395064-25-000095, leaves this page and opens in a new tabForm20-FFiledJun 25, 2025PeriodFY2025Accession0001395064-25-000095What we read from itBalance sheetFY2025Open on SEC.gov, accession 0001395064-25-000095, leaves this page and opens in a new tabForm20-FFiledJun 25, 2025PeriodFY2025Accession0001395064-25-000095What we read from itCash flow statementFY2025Open on SEC.gov, accession 0001395064-25-000095, leaves this page and opens in a new tab | |||
| 5/9 | FY2025 | Jun 25, 2025 | |
FormulaOne point each for: positive return on assets, positive operating cash flow, rising return on assets, operating cash flow above net income, falling leverage, rising current ratio, no new shares issued, rising gross margin, rising asset turnover. As ofThe filing date of the statements below, for FY2025. Form20-FFiledJun 25, 2025PeriodFY2025Accession0001395064-25-000095What we read from itIncome statementFY2025Open on SEC.gov, accession 0001395064-25-000095, leaves this page and opens in a new tabForm20-FFiledJun 25, 2025PeriodFY2025Accession0001395064-25-000095What we read from itBalance sheetFY2025Open on SEC.gov, accession 0001395064-25-000095, leaves this page and opens in a new tabForm20-FFiledJun 25, 2025PeriodFY2025Accession0001395064-25-000095What we read from itCash flow statementFY2025Open on SEC.gov, accession 0001395064-25-000095, leaves this page and opens in a new tab | |||
The figures are computed from the accounts for fiscal 2025, the newest full year on file. 9 filed fiscal years on record, FY2017 to FY2025, from SEC EDGAR. Prices as of Oct 15, 2026. Ratios recomputed Oct 14, 2026. Two facts, because a recompute is not a fresh quote.
The year and the filing date name the statement each figure’s accounts are read from, and they stand even where the figure itself could not be computed: the line beneath a blank says what that statement did not carry. A figure’s name opens its formula and the filings behind it; a statement that names no SEC filing has no filing date, and reads n/a.
Ten years of filed figures, year by year
Ten years of filed figures
10 fiscal years, FY2016 to FY2025. 9 read from the annual reports Takeda Pharmaceutical Company Limited filed with the SEC, each naming its filing; the rest from statements that name none, which are market data. Amounts in JPY, as reported.
| Year | Revenue | Operating income | Net income | EPS, diluted | Free cash flow | Operating margin | Return on equity | Filing |
|---|---|---|---|---|---|---|---|---|
| FY2025 | 4.58T | 342.59B | 107.93B | n/a | 856.39B | 7.5% | 1.6% | 20-F, Jun 25, 20250001395064-25-000095 |
| FY2024 | 4.26T | 214.07B | 144.07B | n/a | 540.92B | 5.0% | 2.0% | 20-F, Jun 26, 20240001395064-24-000086 |
| FY2023 | 4.03T | 490.50B | 317.02B | n/a | 836.50B | 12.2% | 5.0% | 20-F, Jun 28, 20230001395064-23-000072 |
| FY2022 | 3.57T | 460.84B | 230.06B | n/a | 999.85B | 12.9% | 4.0% | 20-F, Jun 29, 20220001395064-22-000107 |
| FY2021 | 3.20T | 509.27B | 376.00B | n/a | 899.73B | 15.9% | 7.3% | 20-F, Jun 29, 20210001395064-21-000140 |
| FY2020 | 3.29T | 100.41B | 44.24B | n/a | 542.67B | 3.0% | 0.9% | 20-F, Jun 24, 20200001395064-20-000110 |
| FY2019 | 2.10T | 237.69B | 135.19B | n/a | 250.80B | 11.3% | 2.6% | 20-F, Jun 27, 20190001395064-19-000005 |
| FY2018 | 1.77T | 241.79B | 186.89B | n/a | 310.85B | 13.7% | 9.4% | 20-F, Jun 27, 20190001395064-19-000005 |
| FY2017 | 1.73T | 155.87B | 114.94B | n/a | 199.70B | 9.0% | n/a | 20-F, Jun 27, 20190001395064-19-000005 |
| FY2016 | 1.81T | 130.83B | 80.17B | 50.86 | -59.37B | 7.2% | 4.1% | Market data, supplied Oct 15, 2026accession n/a |
- Revenue, compound annual growth FY2016 to FY2025: 10.9%
- Earnings, compound annual growth FY2016 to FY2025: 3.4%
- Earnings per share: Fewer than two filed years carry earnings per share.
- Free cash flow: Free cash flow was not positive in both 2016 and 2025, so a compound rate across the window is not defined. Both figures are in the table.
Every figure in this section is a line of a filed annual statement or a ratio of two of them. Nothing here is estimated or smoothed. Earnings per share filed before a share split are put on today's share count, and say so. Nothing here is a verdict on the company.
8 of 10
Risks and guardrails
The accounting screens, the published tests, and the lines you can set to be told.
ComputedCompany statement
| Figure | Value, source and document |
|---|---|
| Beneish M-score | -2.73 ComputedFY2025 20-F, filed Jun 25, 2025, 0001395064-25-000095 |
| Piotroski F-score | 5/9 ComputedFY2025 20-F, filed Jun 25, 2025, 0001395064-25-000095 |
| Named tests met | 1 of 30 Computed |
| Beta | 0.05 ComputedClose of Oct 15, 2026 |
The named tests
Of 30 tests value investors published: 1 met, 27 not met, 2 we could not complete. Counts, never a score: a single figure would have to decide that meeting one investor’s criteria and meeting another’s are worth the same.
Which tests, by name(all 30)
- Meets
- Cash-covered dividend
- Does not
- Defensive investor (Benjamin Graham); Deep value; Large cap, low P/E; Earnings yield and ROIC (Joel Greenblatt); High F-score, low P/B (Joseph Piotroski); Three forensic scores; Low PEG, low debt (Peter Lynch); High returns and growth; Gross margin, turnover (Robert Novy-Marx); EV/EBITDA and coverage; High yield, low payout; Low beta, profitable; ROIC at or above WACC; Near the 52-week low; Z-score and coverage (Edward Altman); Two thirds of NCAV (Benjamin Graham); High returns, low debt; Owner earnings yield; High return on tangibles; Low P/S, rising earnings (James O'Shaughnessy); Book or below, low debt (Walter Schloss); Tangible book or below; Cash-flow yield and ROIC; Clean books, high ROIC; Cheapest quarter on P/E (David Dreman); Cheapest quarter on P/B (David Dreman); Low P/E, growth, yield (John Neff)
- Not measured
- Dividends and buybacks; P/E times P/B (Benjamin Graham). A test with a figure we could not read is incomplete, never met and never failed.
Figures we could not read(7)
- Positive Earnings Streak: The latest filed year has no per-share earnings we can read; the test needs 10.
- PEG Ratio: We do not hold this figure for this company, so there is nothing to show.
- Eps Growth 5Y: We do not hold this figure for this company, so there is nothing to show.
- Dividend Yield: The newest cash flow statement on file ended more than fifteen months ago, so it says nothing about today's yield.
- Share Count Change Yoy: We do not hold this figure for this company, so there is nothing to show.
- Price To Graham: We do not hold this figure for this company, so there is nothing to show.
- Price Tangible Book: We do not hold this figure for this company, so there is nothing to show.
9 of 10
Declared positions
Whether anybody here owns this company.
Positions declared by Javier Sanz Alvarez: no holding in any company shown here, as of October 3, 2026.
10 of 10
Next step
What to do with what you have read.
A thesis is your reason for owning it, in your words, with the figures that must stay true. Checking those figures every night against the newest filed accounts, and telling you once when one breaks, is what the subscription adds.
What this cannot tell you
- 7 figures could not be read on this company, among them Positive Earnings Streak, PEG Ratio, Eps Growth 5Y. Each blank in the table above names the rest, with its reason. 2 named tests come back incomplete because of them, which is neither met nor missed.
- We hold 9 filed fiscal years rather than 10, so the run above is shorter than a full decade and is counted as what it is.
And the one that is true of all of it: This is what the numbers say today. It cannot tell you the day one of them stops being true. Nothing here can, because the reasons are not written down.
Running this once is arithmetic on public documents and you are welcome to it. Writing down why you own each company, in your own words and with the numbers that have to stay true for it to hold, and then having those numbers re-checked every night against the newest filed accounts, and against the latest close where a rule watches a price, is Professional, the plan a new account starts on for 30 days, one trial per person. It writes to you the day one breaks, and stays quiet when nothing does. The check runs every night at 23:30 UTC. A filing is picked up the night after it is published.
No card. 30 free days, and nothing is charged unless you choose a plan.
ValueScreener · valuescreener.ai · Computed from accounts filed with the SEC by this company, read from EDGAR, and from dated closing prices. On this page a filed figure opens into its formula, its inputs and the statement, fiscal year and filing date it was read from, and a price into the day of its close. A figure that cannot show that trail says so.
A computation on accounts filed with the SEC, not a recommendation and not advice. Past filings do not indicate future results. Risk disclaimer.